Grant: Planning and Dissemination Grant - Institute Community Support
University of Alberta
$25,000.00
Engagement and Planning for the Canadian Right Ventricular Adaptive Platform Trial
EF 2022-23
Résumé
Pulmonary hypertension can be caused by many lung and heart diseases. Pulmonary hypertension leads to failure of the right ventricle of the heart. Unlike left ventricular failure, there are no proven treatments for right ventricular failure. We are planning a platform trial called the Canadian Right ventricular AdaptiVE trial (CRAVE). Platform trials are an innovative way to study several potential treatments at once. This will be the first clinical trial using this design for patients with pulmonary hypertension or right ventricular failure. In order to ensure the CRAVE trial meets the priorities of patients and other key stakeholders, our grant aims to plan and execute a planning meeting with patients with pulmonary hypertension and caregivers, researchers and trial experts. This meeting will occur over 1.5 days in September 2023 and will help inform decisions about key objectives and elements for this platform trial. This meeting grant will ensure that the CRAVE platform trial aligns with patient priorities and needs. The next steps after this meeting will be to write a CRAVE protocol and apply for funding to develop and run the CRAVE platform trial. This initiative has the potential to improve patients' participation and input in trial design, improve access for participating in research, and to more efficiently study treatments for this deadly condition.
Programme
Planning and Dissemination Grant - Institute Community Support
Bénéficiaire
Emplacement
Alberta, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
480761
Name
Weatherald Jason
Region
Alberta
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Circulatory and Respiratory Health
Theme2
Clinical
Prcname2
Planning and Dissemination Grants
Projecttitle
Engagement and Planning for the Canadian Right Ventricular Adaptive Platform Trial
Programtype2
Miscellaneous Programs
Orgnameinp2
University of Alberta
Cihramount2
$25,000
Cihrequipment2
$0
Programname2
Planning and Dissemination Grant - Institute Community Support
Keyworddelim
Engagement; Innovative Clinical Trials; Platform Trial; Pulmonary Hypertension; Right Ventricle
Abstract
Pulmonary hypertension can be caused by many lung and heart diseases. Pulmonary hypertension leads to failure of the right ventricle of the heart. Unlike left ventricular failure, there are no proven treatments for right ventricular failure. We are planning a platform trial called the Canadian Right ventricular AdaptiVE trial (CRAVE). Platform trials are an innovative way to study several potential treatments at once. This will be the first clinical trial using this design for patients with pulmonary hypertension or right ventricular failure. In order to ensure the CRAVE trial meets the priorities of patients and other key stakeholders, our grant aims to plan and execute a planning meeting with patients with pulmonary hypertension and caregivers, researchers and trial experts. This meeting will occur over 1.5 days in September 2023 and will help inform decisions about key objectives and elements for this platform trial. This meeting grant will ensure that the CRAVE platform trial aligns with patient priorities and needs. The next steps after this meeting will be to write a CRAVE protocol and apply for funding to develop and run the CRAVE platform trial. This initiative has the potential to improve patients' participation and input in trial design, improve access for participating in research, and to more efficiently study treatments for this deadly condition.
Competitiondate
202302
Approvedterm2
1 yr 0 mth
Pinamesdelim
Weatherald, Jason; Lawler, Patrick R; Mielniczuk, Lisa M; Stewart, Duncan J
Approvedterm
1 an 0 mois
Cihrcontribution2
SPOR~ $25,000~ $0~